Table 1.

Neuropathological diagnostics and genetic characterization of samples used for patient‐derived xenografts

Xenografts	Histopathological diagnosis	Molecular pathology (methylation score)	Survival (days)	IDH status	1p/19q Codel	ATRX mutation	CDKN2A/B deletion	RTK amplified	Gain of Chr7	Loss of Chr10
E478	Oligodendroglioma grade III	NA	73 days	IDH1‐R132Hb	Yesa	NA	Noa	Noa	Yesa	Yesa
T186	Anaplastic oligodendroglioma grade III	NA	107 days	IDH1‐R132Hb	Noa	Yesb (E1473)	Noa	Noa	Noa	Partiala
T394	Glioblastoma grade IV	Glioma, IDH mutant, subclass high‐grade astrocytoma (0.99)	77 days	IDH1‐R132Hb	Partiala	Unclear significanceb ,  c	Yesa	PDGFRAa	Noa	Partiala
P3	Glioblastoma grade IV	NA	40 days	Nob	Noa	Nob	Yesa	Noa	Yesa	Partiala
P8	Glioblastoma grade IV	NA	58 days	Nob (V178I)	Noa	Unclear significanceb ,  d	Yesa	EGFRa	Yesa	Yesa
T434	Glioblastoma grade IV	Glioblastoma, IDH wild‐type (0.99)	42 days	Nob	Noa	Nob	Noa	EGFRa	Partiala	Yesa

NA: not assessed; ATRX E1473: Nonsense mutation, SIFT & Polyphen‐2 score deleterious.

IDH1 V178I – no functional domain affected, 2‐HG unaffected.

^aArray comparative genomic hybridization.

^bTargeted next generation sequencing.

^cATRX Q891E – hypomorphic mutation, protein features might be affected; additional 15 missense mutations with unclear significance.

^dATRX Q891E – hypomorphic mutation, protein features might be affected; additional S502C missense mutation with unclear significance.